Jazz Pharmaceuticals plc (JAZZ)
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants Amal Melhem-Bertrandt Philip Johnson - Executive VP & CFO Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Thank you very much for joining us today. My name is Mohit Bansal.
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.
Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Bruce C. Cozadd - Co-Founder, Chairman & CEO Jack Spinks - Corporate Participant Philip L.
Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of $8.25 per share versus the Zacks Consensus Estimate of a loss of $6.12. This compares to earnings of $5.3 per share a year ago.
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
In recent months, Jazz Pharmaceuticals plc has remained a stock that has seen some decline in attention from retail investors. This comes amid the potential approval of Zepzelca in combination with Tecentriq as a therapy for first-line extensive-stage small cell lung cancer. Meanwhile, the crown jewel of Jazz Pharmaceuticals' oncology franchise is Ziihera, which is superior in efficacy to chemotherapy drugs and Enhertu in the treatment of biliary tract cancer and more.
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Jazz Pharmaceuticals: One Step Forward, One Back
Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. The oxybate business experienced a setback when Avadel won the appeal that allows Lumryz to compete with Jazz's Xywav in idiopathic hypersomnia. There are three potential catalysts for the oncology business in the second half of the year that should translate to a revenue growth inflection point in 2026.
